AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06325943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6
Study NCT06325943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6
Study NCT03174795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
Study NCT03174795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
Study NCT04504084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
Study NCT03202875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR341402
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03202875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03240432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom CGM
Description: CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
Study NCT05118438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion Nursing Intervention
Description: A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
Study NCT03644446 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bisoprolol plasma residual concentration dosage
Description: Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal > 60mL/min as estimated by the CKD-EPI formula)
Study NCT04299425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRAF Detection Technology
Description: Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio > 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.
Study NCT02271919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Lozenge
Description: Given PO
Study NCT02271919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Patch
Description: Given via patch
Study NCT02271919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO or via patch
Study NCT02271919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO or via patch
Study NCT02271919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive behavioral smoking cessation counseling
Study NCT02271919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive behavioral smoking cessation counseling
Study NCT02271919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO
Study NCT03496025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation
Description: The intervention consists of activating paralyzed facial muscles with electrical stimulation.
Study NCT02344303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Study NCT02344303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT02344303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00951561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vipon
Description: The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
Study NCT00951561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg daily
Study NCT02092987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social work support
Description: All study participants were provided access to social support services at Riverstone Senior Life services
Study NCT02092987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social work support
Description: All study participants were provided access to social support services at Riverstone Senior Life services
Study NCT02092987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational material
Description: All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
Study NCT02138110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold
Description: Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
Study NCT02092987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational material
Description: All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
Study NCT02092987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NYU caregiver counseling intervention
Description: The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers.
Study NCT02092987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REACH OUT counseling intervention
Description: All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed
Study NCT02189863 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MF
Description: Multifocal contact lenses worn in both eyes
Study NCT02189863 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B MV
Description: Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
Study NCT02189863 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B SVD
Description: Spherical contact lenses worn with both eyes corrected for distance
Study NCT02189863 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A MF
Description: Multifocal contact lenses worn in both eyes
Study NCT00427388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
Study NCT01888198 — intervention group
Intervention type: BEHAVIORAL
Intervention: (EORTC QLQ-C30) questionnaire
Study NCT01888198 — intervention group
Intervention type: BEHAVIORAL
Intervention: EuroQol EQ-5D 7-item questionnaire
Study NCT00427388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
Study NCT04034979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: decision aid
Description: One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
Study NCT01110070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ChonDux
Description: Comparison of ChonDux plus microfracture to microfracture only
Study NCT01110070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ChonDux
Description: single use device
Study NCT02424214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Oocyte activation
Study NCT02424214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca Ionophore
Study NCT02424214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strontium Chloride
Study NCT03312751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab will be administered by intravenous infusion, twice weekly.
Study NCT00375947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Exercise
Study NCT00375947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham hand cream
Description: placebo intervention
Study NCT02402842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin and 5-Fluorouracil
Description: Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
Study NCT00442468 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study.
Description: This is a non-interventional (no drug treatment administered), prevalence (observational) study.
Study NCT00458497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holofiber fabric
Description: Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
Study NCT00458497 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PET fabric
Description: Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
Study NCT00931346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate
Study NCT00931346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03342300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
Study NCT03342300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pirarubicin
Description: Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
Study NCT02483052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir
Description: RejuvenAir
Study NCT02718950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Description: Subjects will use liraglutide 3.0 mg for 2 weeks
Study NCT02963961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Cognitive Training Battery
Description: Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
Study NCT02189863 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Contact lenses worn in both eyes per subject's habitual prescription
Study NCT04898998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
Study NCT04898998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Description: routine care
Study NCT01339494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine and citrulline supplementations
Description: Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
Study NCT02784652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
Study NCT04301258 — intervention group
Intervention type: OTHER
Intervention: Articular cartilage repair
Description: Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
Study NCT02784652 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
Study NCT05943483 — intervention group
Intervention type: OTHER
Intervention: CCMQ questionnaire
Description: Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.
Study NCT03980405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1- Control Diet
Description: Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
Study NCT03980405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2- UCD Diet
Description: Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
Study NCT01807026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Study NCT01807026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04837469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fissure sealant application
Description: fissure sealants were placed after differnt adhesive strategies used
Study NCT01391299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
Study NCT01391299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
Study NCT03909581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic coronary arterial bypass
Description: is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
Study NCT03909581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: will be performed using standard techniques at the discretion of the operator (50 participants)
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 5mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 20mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose.
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 80mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 120mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study NCT02230579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study NCT02619708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Preoperative Experience
Description: The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
Study NCT03116451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot Health Promoting Program
Description: An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
Study NCT03702270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penicillin Allergic Risk Stratification Best Practice Alert
Description: Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
Study NCT00827268 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: One-on-one treatment of reading difficulties
Description: Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
Study NCT02584621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself App with Feedback
Study NCT01874704 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comparison of biomarkers of stress
Study NCT03046238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
Study NCT03046238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
Study NCT02553603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone (GHRH)
Description: Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
Study NCT02553603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone Releasing Hormone
Description: Placebo GHRH to be given once daily for 10 weeks
Study NCT02533960 — intervention group
Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention.
Study NCT00613197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova
Description: 4g/day in divided doses
Study NCT00613197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epanova
Description: 4g/day in divided doses
Study NCT00597844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voice evaluation and fMRI
Description: will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
Study NCT00597844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: undergo voice evaluation and fMRI prior
Description: in approximately one month and six months
Study NCT03865706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin Oral Suspension
Description: Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
Study NCT03865706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Suspension
Description: 250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
Study NCT03865706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Description: Standard of care treatment for infections